07/02/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/2/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the BD Veritor™ System for Rapid Detection of SARS-CoV-2. The BD Veritor™ System for Rapid Detection of SARS-CoV-2 is authorized for use using nasal swab specimens collected from individuals who are suspected of COVID-19 by their healthcare provider within the first five days of the onset of symptoms. (PDF)
No hay comentarios:
Publicar un comentario